Compare Repligen Corporation Common Stock (RGEN) vs WisdomTree Inc. Common Stock (WT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs WisdomTree Inc. Common Stock — how do they compare? Repligen Corporation Common Stock trades at $178.19 (market cap $11.14B), while WisdomTree Inc. Common Stock trades at $21.02 (market cap $3.27B). The key difference: Repligen Corporation Common Stock is far larger — about 3.4× WisdomTree Inc. Common Stock's market cap, and WisdomTree Inc. Common Stock pays a 0.56% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and WisdomTree Inc. Common Stock for 6 Days on average.
| RGEN | WT | |
|---|---|---|
Market Cap | $11.14B | $3.27B |
Volume | 1,259,263 | 2,488,313 |
Sector | Health | Financials |
52-Week High | $194.57 | $25.04 |
52-Week Low | $102.87 | $10.73 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $11.02B | $4.02B |
Dividend Yield | — | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
WisdomTree (WT) trades at $21.61, down 2.83% on the day, near the analyst low target of $21.30. The stock shows bearish technical signals with mixed oscillators, while fundamentals reveal strong profitability margins and consistent earnings beats. Recent news highlights WisdomTree's expansion into tokenized funds and new ETF launches, signaling growth initiatives.
The outlook is cautiously optimistic given analyst consensus favoring Buy ratings and a $26.05 price target, but risks include high valuation multiples and negative investing cash flow trends. Earnings momentum from recent beats supports upside potential, though investors face volatility from market sentiment and execution risks in new business lines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About WisdomTree Inc. Common Stock
WisdomTree provides exchange-traded products, model portfolios, and digital-asset-related products and services. Its digital offerings include tokenized funds, an institutional platform, and a blockchain-native wallet.
Read more on WT →
